Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CTSO
stocks logo

CTSO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
10.38M
+2.74%
-0.047
-66.66%
9.69M
+11%
-0.040
+100%
10.60M
+10.2%
-0.035
-216.67%
Estimates Revision
The market is revising No Change the revenue expectations for Cytosorbents Corporation (CTSO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.47%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-23.47%
In Past 3 Month
Wall Street analysts forecast CTSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSO is 0.75 USD with a low forecast of 0.75 USD and a high forecast of 0.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CTSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSO is 0.75 USD with a low forecast of 0.75 USD and a high forecast of 0.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 0.739
sliders
Low
0.75
Averages
0.75
High
0.75
Current: 0.739
sliders
Low
0.75
Averages
0.75
High
0.75
H.C. Wainwright
Sean Lee
Neutral
downgrade
$1
2025-11-14
Reason
H.C. Wainwright
Sean Lee
Price Target
$1
2025-11-14
downgrade
Neutral
Reason
H.C. Wainwright analyst Sean Lee lowered the firm's price target on CytoSorbents to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates to reflect to the "continued drag" on the company's Germany revenues.
HC Wainwright & Co.
Sean Lee
Hold
Reiterates
$1
2025-04-03
Reason
HC Wainwright & Co.
Sean Lee
Price Target
$1
2025-04-03
Reiterates
Hold
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-04-01
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-04-01
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-01-13
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-01-13
Maintains
Strong Buy
Reason
D. Boral Capital says CytoSorbents reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents' strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-01-03
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-01-03
Maintains
Strong Buy
Reason
D. Boral Capital says CytoSorbents reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents' strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cytosorbents Corp (CTSO.O) is -4.87, compared to its 5-year average forward P/E of -10.99. For a more detailed relative valuation and DCF analysis to assess Cytosorbents Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.99
Current PE
-4.87
Overvalued PE
3.96
Undervalued PE
-25.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-103.53
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
253.12
Undervalued EV/EBITDA
-460.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.22
Current PS
0.00
Overvalued PS
5.69
Undervalued PS
0.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CTSO News & Events

Events Timeline

(ET)
2025-11-13
16:18:48
CytoSorbents Launches Program to Reduce Workforce and Costs
select
2025-11-13
16:17:35
CytoSorbents announces Q3 adjusted EPS of 4 cents, below consensus estimate of 5 cents.
select
2025-09-16 (ET)
2025-09-16
07:09:03
CytoSorbents announces regulatory progress for DrugSorb-ATR
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-18PRnewswire
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

  • Company Presentation: CytoSorbents Corporation will present at the Jefferies Global Healthcare Conference from November 17-20, 2025, with a specific presentation scheduled for November 18 at 12:30 PM GMT.

  • Product Overview: The company specializes in blood purification technologies for critical care, with its lead product, CytoSorb, approved in the EU and used in over 70 countries to remove toxins and inflammatory agents from blood.

  • Regulatory Developments: CytoSorbents is pursuing FDA approval for its investigational DrugSorb™-ATR system, aimed at reducing perioperative bleeding in high-risk surgeries, and has received Breakthrough Device Designations for specific anticoagulant removals.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the company's plans and regulatory submissions, cautioning that actual results may differ due to various risks and uncertainties.

[object Object]
Preview
4.0
11-15NASDAQ.COM
HC Wainwright & Co. Upholds Neutral Rating for Cytosorbents (CTSO)

  • Analyst Recommendation: HC Wainwright & Co. maintains a Neutral recommendation for Cytosorbents (NasdaqCM:CTSO) as of November 14, 2025, with a projected one-year price target of $5.10/share, indicating a potential upside of 672.73% from its current price of $0.66/share.

  • Projected Revenue and EPS: Cytosorbents is expected to see a significant increase in annual revenue, projected at $122 million, which represents a 237.10% growth, alongside a projected non-GAAP EPS of 0.17.

  • Fund Sentiment: There are currently 73 funds reporting positions in Cytosorbents, reflecting an 8.96% increase in ownership over the last quarter, with total institutional shares rising by 1.15% to 18,005K shares.

  • Shareholder Activity: Notable changes in shareholder allocations include Avenir increasing its stake slightly, while Skylands Capital and Neuberger Berman Group both reduced their holdings significantly over the last quarter.

[object Object]
Preview
9.5
11-14PRnewswire
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

  • Financial Performance: CytoSorbents Corporation reported a 10% year-over-year revenue increase to $9.5 million in Q3 2025, with improved gross margins of 70% and a reduced operating loss of $2.9 million.

  • Strategic Initiatives: The company implemented a Workforce and Cost Reduction Program aimed at achieving cash-flow breakeven by Q1 2026, alongside an amended credit agreement providing an additional $2.5 million in funding.

  • Regulatory Progress: CytoSorbents submitted a De Novo pre-submission package for its DrugSorb™-ATR device to the FDA, with a formal application expected in Q1 2026 and a regulatory decision anticipated by mid-2026.

  • Clinical Advancements: Recent clinical data and presentations highlighted the effectiveness of CytoSorb's therapies in managing sepsis and anticoagulant removal during cardiac surgery, reinforcing the company's commitment to improving patient outcomes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cytosorbents Corp (CTSO) stock price today?

The current price of CTSO is 0.739 USD — it has increased 1.23 % in the last trading day.

arrow icon

What is Cytosorbents Corp (CTSO)'s business?

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.

arrow icon

What is the price predicton of CTSO Stock?

Wall Street analysts forecast CTSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSO is 0.75 USD with a low forecast of 0.75 USD and a high forecast of 0.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cytosorbents Corp (CTSO)'s revenue for the last quarter?

Cytosorbents Corp revenue for the last quarter amounts to 9.49M USD, increased 10.12 % YoY.

arrow icon

What is Cytosorbents Corp (CTSO)'s earnings per share (EPS) for the last quarter?

Cytosorbents Corp. EPS for the last quarter amounts to -0.05 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cytosorbents Corp (CTSO)'s fundamentals?

The market is revising No Change the revenue expectations for Cytosorbents Corporation (CTSO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.47%.
arrow icon

How many employees does Cytosorbents Corp (CTSO). have?

Cytosorbents Corp (CTSO) has 149 emplpoyees as of December 05 2025.

arrow icon

What is Cytosorbents Corp (CTSO) market cap?

Today CTSO has the market capitalization of 46.41M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free